Acceleron Pharma Stock Price, News & Analysis (NASDAQ:XLRN)

$45.02 -0.10 (-0.22 %)
(As of 01/17/2018 06:04 AM ET)
Previous Close$45.12
Today's Range$44.93 - $46.54
52-Week Range$23.07 - $46.54
Volume350,600 shs
Average Volume358,370 shs
Market Capitalization$1.99 billion
P/E Ratio-17.45
Dividend YieldN/A
Beta1.59

About Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma logoAcceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

Receive XLRN News and Ratings via Email

Sign-up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorBio Therapeutic Drugs
SymbolNASDAQ:XLRN
CUSIPN/A
Phone+1-617-6499200

Debt

Debt-to-Equity RatioN/A
Current Ratio21.63%
Quick Ratio21.63%

Price-To-Earnings

Trailing P/E Ratio-17.4496124031008
Forward P/E Ratio-16.99
P/E GrowthN/A

Sales & Book Value

Annual Sales$27.77 million
Price / Sales73.34
Cash FlowN/A
Price / CashN/A
Book Value$5.98 per share
Price / Book7.53

Profitability

Trailing EPS($2.58)
Net Income$-57,010,000.00
Net Margins-759.34%
Return on Equity-40.70%
Return on Assets-37.44%

Miscellaneous

Employees121
Outstanding Shares45,240,000

Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc (NASDAQ:XLRN) posted its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.02. The biopharmaceutical company had revenue of $3 million for the quarter, compared to analysts' expectations of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The company's quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.55) EPS. View Acceleron Pharma's Earnings History.

When will Acceleron Pharma make its next earnings announcement?

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Acceleron Pharma.

Where is Acceleron Pharma's stock going? Where will Acceleron Pharma's stock price be in 2018?

16 brokers have issued 1-year target prices for Acceleron Pharma's stock. Their forecasts range from $20.00 to $63.00. On average, they anticipate Acceleron Pharma's share price to reach $44.71 in the next year. View Analyst Ratings for Acceleron Pharma.

What are Wall Street analysts saying about Acceleron Pharma stock?

Here are some recent quotes from research analysts about Acceleron Pharma stock:

  • 1. Cann analysts commented, "Acceleron announced today preliminary results from the first two cohorts in Part 1 of the phase II clinical study of ACE-083 in patients with facioscapulohumeral dystrophy (FSHD). Results from the tibialis anterior cohort demonstrated patients treated with ACE-083 generated a mean total muscle volume increase of 12.6%; this was associated with a mean improvement in muscle fat fraction of 5.3%. Results from the biceps brachii cohort of the studyl demonstrated patients treated with ACE-083 generated a mean total muscle volume gain of 13.2%; this was associated with a mean improvement in muscle fat fraction of 0.6%." (1/8/2018)
  • 2. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (8/9/2017)
  • 3. Instinet analysts commented, "We are initiating coverage of Acceleron (XLRN) with a Buy rating and $58 target price. We recommend owning XLRN shares ahead of what we view as underappreciated 2H17 readouts. We foresee upside to the shares following positive results in 2H17 from a Phase 2 study of ACE-083, a myostatin+ inhibitor in FSHD. ACE-083 is a wholly owned program that is not currently ascribed value in XLRN's share price but worth $19/sh, by our estimate. We believe that these near-term data have been obscured by investors' focus on pivotal 2H18 Phase 3 results from Celgene-partnered (20-25% royalties) blockbuster luspatercept in MDS and beta-thalassemia. We expect further share price appreciation from this program in 2H17, as Phase 2 extension data for luspatercept better frames the magnitude of, and potential upside to, the market opportunity from indication expansion in myeloid diseases outside beta-thalassemia and MDS." (3/1/2017)

Who are some of Acceleron Pharma's key competitors?

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the folowing people:

  • Francois E. Nader M.D., Independent Chairman of the Board (Age 60)
  • Habib J. Dable, President, Chief Executive Officer, Director (Age 47)
  • Kevin F. McLaughlin, Chief Financial Officer, Senior Vice President, Treasurer (Age 60)
  • Matthew L. Sherman M.D., Executive Vice President and Chief Medical Officer (Age 61)
  • Ravindra Kumar Ph.D, Senior Vice President, Chief Scientific Officer (Age 57)
  • John D. Quisel J.D., Ph.D., Senior Vice President, Business Development, General Counsel and Secretary (Age 45)
  • Karen L. Smith M.D. Ph.D., Director
  • Jean M. George, Independent Director (Age 59)
  • George S. Golumbeski Ph.D., Independent Director (Age 59)
  • Terrence C. Kearney, Independent Director (Age 62)

How do I buy Acceleron Pharma stock?

Shares of Acceleron Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of Acceleron Pharma stock can currently be purchased for approximately $45.02.

How big of a company is Acceleron Pharma?

Acceleron Pharma has a market capitalization of $1.99 billion and generates $27.77 million in revenue each year. The biopharmaceutical company earns $-57,010,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis. Acceleron Pharma employs 121 workers across the globe.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 Sidney St, CAMBRIDGE, MA 02139-4239, United States. The biopharmaceutical company can be reached via phone at +1-617-6499200.


MarketBeat Community Rating for Acceleron Pharma (XLRN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  446
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Acceleron Pharma (NASDAQ:XLRN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.562.562.592.60
Ratings Breakdown: 1 Sell Rating(s)
5 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $44.71$44.71$43.67$42.54
Price Target Upside: 6.18% upside24.48% upside12.66% upside34.70% upside

Acceleron Pharma (NASDAQ:XLRN) Consensus Price Target History

Price Target History for Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma (NASDAQ:XLRN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2018CannReiterated RatingHoldHighView Rating Details
1/8/2018OppenheimerReiterated RatingHoldMediumView Rating Details
12/11/2017HC WainwrightReiterated RatingBuy$62.00MediumView Rating Details
11/14/2017Credit Suisse GroupSet Price TargetBuy$35.00 -> $51.00N/AView Rating Details
11/2/2017Royal Bank of CanadaReiterated RatingHoldN/AView Rating Details
9/20/2017BarclaysBoost Price TargetOverweight$42.00 -> $50.00HighView Rating Details
8/4/2017CitigroupBoost Price TargetBuy$44.00HighView Rating Details
7/28/2017Piper Jaffray CompaniesReiterated RatingBuy$40.00MediumView Rating Details
6/14/2017InstinetReiterated RatingBuy$58.00LowView Rating Details
6/13/2017FBR & CoSet Price TargetBuy$63.00HighView Rating Details
6/13/2017Morgan StanleyLower Price TargetOverweight$51.00 -> $42.00HighView Rating Details
6/13/2017CIBCDowngradeOutperform -> Market PerformLowView Rating Details
5/17/2017Goldman Sachs GroupInitiated CoverageSell -> Sell$20.00HighView Rating Details
5/1/2017JMP SecuritiesReiterated RatingOutperform$39.00LowView Rating Details
3/14/2017JPMorgan Chase & Co.Initiated CoverageNeutral -> Neutral$33.00HighView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
12/1/2016Leerink SwannSet Price TargetBuy$50.00N/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageBuy$46.00N/AView Rating Details
2/29/2016Janney Montgomery ScottUpgradeNeutral -> Buy$45.00 -> $39.00N/AView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Acceleron Pharma (NASDAQ:XLRN) Earnings History and Estimates Chart

Earnings by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma (NASDAQ XLRN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($0.60)N/AView Earnings Details
11/7/2017Q3 2017($0.67)($0.65)$3.52 million$3.00 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.65)($0.77)$3.69 million$3.10 millionViewListenView Earnings Details
5/8/20173/31/2017($0.58)($0.66)$3.38 million$3.71 millionViewListenView Earnings Details
3/1/2017Q416($0.55)($0.51)$3.74 million$3.37 millionViewListenView Earnings Details
11/3/2016Q316($0.53)($0.55)$4.08 million$3.00 millionViewListenView Earnings Details
8/4/2016Q216($0.50)($0.59)$3.77 million$3.20 millionViewListenView Earnings Details
5/5/2016Q116($0.26)$0.14$8.70 million$18.20 millionViewListenView Earnings Details
2/25/2016Q415($0.09)($0.81)$15.70 million$3.80 millionViewListenView Earnings Details
11/4/2015Q315($0.46)($0.36)$4.38 million$4.16 millionViewListenView Earnings Details
8/6/2015Q215($0.49)($0.32)$4.23 million$5.72 millionViewListenView Earnings Details
5/7/2015($0.43)($0.45)$3.98 million$4.42 millionViewN/AView Earnings Details
3/2/2015Q414($0.23)($0.55)$12.90 million$3.74 millionViewListenView Earnings Details
11/7/2014($0.27)($0.25)$17.76 million$3.51 millionViewN/AView Earnings Details
8/12/2014($0.55)($0.54)$4.08 millionViewN/AView Earnings Details
5/15/2014Q114($0.44)($0.30)$2.85 million$3.31 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.64)$13.66 million$11.50 millionViewN/AView Earnings Details
11/6/2013($0.19)($5.62)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Acceleron Pharma (NASDAQ:XLRN) Earnings Estimates

2018 EPS Consensus Estimate: ($2.33)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.57)($0.57)($0.57)
Q2 20181($0.59)($0.59)($0.59)
Q3 20181($0.59)($0.59)($0.59)
Q4 20181($0.58)($0.58)($0.58)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Acceleron Pharma (NASDAQ:XLRN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Acceleron Pharma (NASDAQ XLRN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 85.70%
Insider Trades by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma (NASDAQ XLRN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/4/2018Kevin F MclaughlinCFOSell19,000$42.89$814,910.0045,300View SEC Filing  
1/3/2018Christopher RovaldiSVPSell2,266$42.42$96,123.7252,977View SEC Filing  
1/3/2018Matthew L ShermanEVPSell4,633$42.71$197,875.4377,700View SEC Filing  
1/2/2018Kevin F MclaughlinCFOSell4,000$42.42$169,680.0045,300View SEC Filing  
12/15/2017Jean GeorgeDirectorSell105,122$35.73$3,756,009.061,250View SEC Filing  
9/25/2017Corp /De/ CelgeneMajor ShareholderBuy745,592$37.00$27,586,904.006,118,479View SEC Filing  
9/13/2017John D QuiselSVPSell5,113$38.42$196,441.4657,918View SEC Filing  
9/12/2017Christopher RovaldiSVPSell14,000$38.41$537,740.0028,232View SEC Filing  
9/12/2017Kevin F MclaughlinCFOSell16,000$38.41$614,560.0050,810View SEC Filing  
9/12/2017Matthew L ShermanEVPSell18,400$38.41$706,744.0079,750View SEC Filing  
8/8/2017Ravindra KumarSVPSell13,065$35.41$462,631.65108,392View SEC Filing  
7/5/2017Kevin F MclaughlinCFOSell34,400$32.00$1,100,800.0080,950View SEC Filing  
7/5/2017Matthew L ShermanEVPSell16,000$32.00$512,000.00112,400View SEC Filing  
7/5/2017Ravindra KumarSVPSell937$32.00$29,984.0096,264View SEC Filing  
1/4/2017Kevin F MclaughlinCFOSell1,700$27.45$46,665.0072,200View SEC Filing  
1/4/2017Matthew L ShermanEVPSell2,000$27.46$54,920.0098,100View SEC Filing  
1/4/2017Steven D ErtelCOOSell2,500$27.44$68,600.00130,977View SEC Filing  
12/30/2016Joseph S ZakrzewskiDirectorBuy4,000$25.50$102,000.004,000View SEC Filing  
12/8/2016Terrance McguireDirectorSell34,928$30.96$1,081,370.881,624View SEC Filing  
11/17/2016Jean GeorgeDirectorSell453,505$38.39$17,410,056.95View SEC Filing  
10/10/2016Ravindra KumarSVPSell52,486$33.92$1,780,325.1291,875View SEC Filing  
9/30/2016Jean GeorgeDirectorSell857,145$35.50$30,428,647.50View SEC Filing  
9/21/2016John D QuiselSVPSell45,952$38.05$1,748,473.6077,004View SEC Filing  
9/12/2016John D QuiselSVPSell21,438$32.14$689,017.3286,723View SEC Filing  
7/6/2016John L KnopfCEOSell100,000$33.87$3,387,000.00147,106View SEC Filing  
7/5/2016John L KnopfCEOSell30,501$33.26$1,014,463.26147,106View SEC Filing  
7/5/2016Steven D ErtelCOOSell32,270$34.56$1,115,251.20137,365View SEC Filing  
7/1/2016John L KnopfCEOSell28,022$34.72$972,923.84147,106View SEC Filing  
7/1/2016Kevin F MclaughlinCFOSell25,300$34.66$876,898.0082,900View SEC Filing  
7/1/2016Matthew L ShermanEVPSell26,000$34.74$903,240.0091,500View SEC Filing  
7/1/2016Steven D ErtelCOOSell28,304$34.77$984,130.08137,365View SEC Filing  
5/20/2016John L KnopfCEOSell100,000$33.07$3,307,000.00160,674View SEC Filing  
4/7/2016Matthew L ShermanEVPSell26,000$32.00$832,000.0095,524View SEC Filing  
4/7/2016Steven D ErtelCOOSell32,270$32.00$1,032,640.00131,098View SEC Filing  
1/11/2016Corp /De/ CelgeneMajor ShareholderBuy800,000$40.00$32,000,000.005,372,887View SEC Filing  
10/15/2015Matthew L. ShermanEVPSell6,000$23.28$139,680.0091,604View SEC Filing  
10/7/2015John L. KnopfCEOSell19,000$24.38$463,220.00119,084View SEC Filing  
10/7/2015Kevin F. MclaughlinCFOSell7,000$24.38$170,660.0080,000View SEC Filing  
9/16/2015Matthew L. ShermanEVPSell2,000$33.24$66,480.0096,404View SEC Filing  
9/15/2015Ravindra KumarVPSell33,000$35.00$1,155,000.0056,685View SEC Filing  
9/15/2015Steven D. ErtelCOOSell2,000$33.61$67,220.00119,656View SEC Filing  
9/14/2015John D. QuiselSVPSell5,500$33.35$183,425.0076,123View SEC Filing  
9/8/2015John L. KnopfCEOSell19,000$30.20$573,800.0021,584View SEC Filing  
9/8/2015Kevin F. MclaughlinCFOSell6,500$30.16$196,040.0040,000View SEC Filing  
8/18/2015Matthew L ShermanEVPSell7,000$31.13$217,910.00View SEC Filing  
8/14/2015John D QuiselSVPSell5,500$30.83$169,565.00View SEC Filing  
7/20/2015Matthew L ShermanEVPSell6,000$32.46$194,760.00View SEC Filing  
7/15/2015Steven D ErtelCOOSell2,000$31.38$62,760.00View SEC Filing  
7/14/2015John D QuiselSVPSell5,500$30.00$165,000.00View SEC Filing  
7/7/2015John L KnopfCEOSell19,000$29.70$564,300.00View SEC Filing  
7/7/2015Kevin F MclaughlinCFOSell7,000$29.70$207,900.00View SEC Filing  
6/18/2015Matthew L ShermanEVPSell7,000$31.54$220,780.00View SEC Filing  
6/15/2015John D QuiselSVPSell5,500$31.13$171,215.00View SEC Filing  
6/15/2015Steven D ErtelCOOSell2,000$31.11$62,220.00View SEC Filing  
6/8/2015John L KnopfCEOSell19,000$32.51$617,690.00View SEC Filing  
6/8/2015Kevin F MclaughlinCFOSell6,500$32.49$211,185.00View SEC Filing  
5/18/2015Matthew L ShermanEVPSell7,000$32.37$226,590.00View SEC Filing  
5/15/2015Steven D ErtelCOOSell2,000$31.49$62,980.00View SEC Filing  
4/20/2015Matthew L ShermanEVPSell5,000$33.52$167,600.00View SEC Filing  
4/15/2015Steven D ErtelCOOSell2,000$33.58$67,160.00View SEC Filing  
4/7/2015John L KnopfCEOSell20,000$34.87$697,400.00View SEC Filing  
4/7/2015Kevin F MclaughlinCFOSell7,000$34.88$244,160.00View SEC Filing  
3/18/2015Matthew L ShermanEVPSell6,000$41.18$247,080.00View SEC Filing  
3/16/2015John D QuiselSVPSell9,500$41.00$389,500.00View SEC Filing  
3/9/2015John L KnopfCEOSell20,000$40.25$805,000.00View SEC Filing  
3/9/2015Kevin F MclaughlinCFOSell6,500$40.25$261,625.00View SEC Filing  
1/20/2015Matthew L ShermanSVPSell7,000$41.64$291,480.00View SEC Filing  
1/15/2015Steven D ErtelSVPSell2,000$40.58$81,160.00View SEC Filing  
1/12/2015Kevin F MclaughlinCFOSell2,000$40.66$81,320.00View SEC Filing  
1/12/2015Ravindra KumarVPSell1,500$40.80$61,200.00View SEC Filing  
1/7/2015John L KnopfCEOSell20,000$39.62$792,400.00View SEC Filing  
1/7/2015Kevin F MclaughlinCFOSell5,000$39.46$197,300.00View SEC Filing  
1/2/2015Ravindra KumarVPSell4,000$38.46$153,840.00View SEC Filing  
1/2/2015Steven D ErtelSVPSell5,000$38.47$192,350.00View SEC Filing  
12/23/2014Edwin M Kania JrDirectorSell54,350$38.00$2,065,300.00View SEC Filing  
12/18/2014Matthew L ShermanSVPSell5,000$40.16$200,800.00View SEC Filing  
12/12/2014John D QuiselSVPSell4,000$41.35$165,400.00View SEC Filing  
12/9/2014Jean GeorgeDirectorSell97,407$44.90$4,373,574.30View SEC Filing  
12/8/2014John L KnopfCEOSell20,000$43.99$879,800.00View SEC Filing  
12/8/2014Kevin F MclaughlinCFOSell10,000$44.02$440,200.00View SEC Filing  
12/8/2014Tom ManiatisDirectorSell23,400$45.00$1,053,000.00View SEC Filing  
12/1/2014Ravindra KumarVPSell4,000$35.88$143,520.00View SEC Filing  
12/1/2014Steven D ErtelSVPSell7,500$35.87$269,025.00View SEC Filing  
11/18/2014Matthew L ShermanSVPSell5,082$33.76$171,568.32View SEC Filing  
11/13/2014Ravindra KumarVPSell16,000$34.53$552,480.00View SEC Filing  
10/28/2014Tom ManiatisDirectorSell23,400$35.00$819,000.00View SEC Filing  
10/8/2014John L KnopfCEOSell20,000$29.71$594,200.00View SEC Filing  
10/8/2014Matthew L ShermanSVPSell5,082$29.50$149,919.00View SEC Filing  
10/7/2014Kevin F MclaughlinCFOSell10,000$29.25$292,500.00View SEC Filing  
10/1/2014Ravindra KumarVPSell11,000$29.89$328,790.00View SEC Filing  
10/1/2014Steven D ErtelSVPSell10,000$29.66$296,600.00View SEC Filing  
9/30/2014John D QuiselSVPSell7,000$30.01$210,070.00View SEC Filing  
9/18/2014Matthew L ShermanSVPSell5,000$25.48$127,400.00View SEC Filing  
9/12/2014John D QuiselSVPSell2,000$25.43$50,860.00View SEC Filing  
9/9/2014John L KnopfCEOSell20,000$24.46$489,200.00View SEC Filing  
9/9/2014Kevin F MclaughlinCFOSell10,000$24.48$244,800.00View SEC Filing  
9/8/2014John L KnopfCEOSell6,700$24.92$166,964.00View SEC Filing  
9/8/2014Kevin F MclaughlinCFOSell3,300$24.90$82,170.00View SEC Filing  
9/3/2014Matthew L ShermanSVPSell5,000$25.82$129,100.00View SEC Filing  
8/18/2014Matthew L ShermanSVPSell2,500$29.62$74,050.00View SEC Filing  
8/14/2014John D QuiselSVPSell13,000$29.98$389,740.00View SEC Filing  
8/14/2014John L KnopfCEOSell17,500$29.78$521,150.00View SEC Filing  
8/14/2014Kevin F MclaughlinCFOSell10,000$29.78$297,800.00View SEC Filing  
8/14/2014Ravindra KumarVPSell9,000$29.97$269,730.00View SEC Filing  
7/18/2014Matthew L ShermanSVPSell2,500$26.22$65,550.00View SEC Filing  
7/14/2014John D QuiselSVPSell5,000$29.73$148,650.00View SEC Filing  
7/9/2014Matthew L ShermanSVPSell7,500$28.99$217,425.00View SEC Filing  
7/7/2014John L KnopfCEOSell17,500$31.74$555,450.00View SEC Filing  
7/7/2014Kevin F MclaughlinCFOSell10,000$31.72$317,200.00View SEC Filing  
7/1/2014Ravindra KumarVPSell2,000$34.10$68,200.00View SEC Filing  
7/1/2014Steven D ErtelSVPSell10,000$34.09$340,900.00View SEC Filing  
6/26/2014Jean GeorgeDirectorSell10,491$35.01$367,289.91View SEC Filing  
6/24/2014Jean GeorgeDirectorSell25,477$35.16$895,771.32View SEC Filing  
6/20/2014Ravindra KumarVPSell7,000$35.00$245,000.00View SEC Filing  
6/18/2014Matthew L ShermanSVPSell2,500$34.42$86,050.00View SEC Filing  
6/13/2014John D QuiselVPSell9,000$33.94$305,460.00View SEC Filing  
6/11/2014Matthew L ShermanSVPSell7,500$33.23$249,225.00View SEC Filing  
6/9/2014John L KnopfCEOSell15,000$31.65$474,750.00View SEC Filing  
6/9/2014Kevin F MclaughlinCFOSell10,000$31.65$316,500.00View SEC Filing  
5/19/2014John KnopfCEOSell15,000$31.52$472,800.00206,500View SEC Filing  
5/19/2014John QuiselVPSell9,000$31.43$282,870.00View SEC Filing  
5/19/2014Steven ErtelSVPSell10,000$31.52$315,200.0027,656View SEC Filing  
5/5/2014Corp /De/ Celgenemajor shareholderBuy1,100,000$42.86$47,146,000.004,572,887View SEC Filing  
5/5/2014Jean GeorgeDirectorSell215,644$42.86$9,242,501.84View SEC Filing  
4/24/2014Edwin Kania, Jr.DirectorSell1,000,000$32.05$32,050,000.004,867View SEC Filing  
4/22/2014Ravindra KumarVPSell2,000$35.86$71,720.0045,890View SEC Filing  
4/22/2014Steven ErtelSVPSell2,500$35.87$89,675.0027,656View SEC Filing  
1/28/2014Corp /De/ CelgeneMajor ShareholderBuy300,000$50.00$15,000,000.00View SEC Filing  
9/24/2013Corp /De/ CelgeneMajor ShareholderBuy666,667$15.00$10,000,005.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Acceleron Pharma (NASDAQ XLRN) News Headlines

Source:
DateHeadline
Stock Review for Biotechs Investors -- Ardelyx, Verastem, and Acceleron PharmaStock Review for Biotech's Investors -- Ardelyx, Verastem, and Acceleron Pharma
www.bizjournals.com - January 11 at 10:56 AM
Acceleron Pharma (XLRN) Stock Rating Reaffirmed by CannAcceleron Pharma (XLRN) Stock Rating Reaffirmed by Cann
www.americanbankingnews.com - January 8 at 5:28 PM
Acceleron Pharma (XLRN) Reports Preliminary Results from Part 1 of ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral DystrophyAcceleron Pharma (XLRN) Reports Preliminary Results from Part 1 of ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy
www.streetinsider.com - January 8 at 4:30 PM
Acceleron Pharma Inc (XLRN) SVP Sells $96,123.72 in StockAcceleron Pharma Inc (XLRN) SVP Sells $96,123.72 in Stock
www.americanbankingnews.com - January 4 at 9:50 PM
Acceleron Pharma Inc (XLRN) CFO Kevin F. Mclaughlin Sells 4,000 SharesAcceleron Pharma Inc (XLRN) CFO Kevin F. Mclaughlin Sells 4,000 Shares
www.americanbankingnews.com - January 4 at 9:50 PM
Insider Selling: Acceleron Pharma Inc (XLRN) EVP Sells 4,633 Shares of StockInsider Selling: Acceleron Pharma Inc (XLRN) EVP Sells 4,633 Shares of Stock
www.americanbankingnews.com - January 4 at 9:50 PM
Kevin F. Mclaughlin Sells 19,000 Shares of Acceleron Pharma Inc (XLRN) StockKevin F. Mclaughlin Sells 19,000 Shares of Acceleron Pharma Inc (XLRN) Stock
www.americanbankingnews.com - January 4 at 9:28 PM
Acceleron Pharma (XLRN) Reports Planned Retirement of Dr. Matthew Sherman from Chief Medical Officer PositionAcceleron Pharma (XLRN) Reports Planned Retirement of Dr. Matthew Sherman from Chief Medical Officer Position
www.streetinsider.com - January 4 at 10:28 AM
Acceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. ShermanAcceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. Sherman
finance.yahoo.com - January 3 at 9:46 AM
Acceleron to Webcast Presentation at the 36th Annual J.P. Morgan Healthcare ConferenceAcceleron to Webcast Presentation at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 10:22 AM
BidaskClub Upgrades Acceleron Pharma (XLRN) to "Buy"BidaskClub Upgrades Acceleron Pharma (XLRN) to "Buy"
www.americanbankingnews.com - December 27 at 9:53 AM
Acceleron Pharma Inc (XLRN) Given Average Rating of "Buy" by BrokeragesAcceleron Pharma Inc (XLRN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 26 at 11:52 AM
Investors Purchase High Volume of Acceleron Pharma Call Options (XLRN)Investors Purchase High Volume of Acceleron Pharma Call Options (XLRN)
www.americanbankingnews.com - December 25 at 1:40 AM
Acceleron Pharma Joins Rank Of Stocks With RS Ratings Over 90Acceleron Pharma Joins Rank Of Stocks With RS Ratings Over 90
finance.yahoo.com - December 22 at 10:46 AM
Zacks: Analysts Anticipate Acceleron Pharma Inc (XLRN) Will Post Quarterly Sales of $3.37 MillionZacks: Analysts Anticipate Acceleron Pharma Inc (XLRN) Will Post Quarterly Sales of $3.37 Million
www.americanbankingnews.com - December 21 at 10:54 AM
Acceleron Pharma Hits 80-Plus Relative Strength Rating BenchmarkAcceleron Pharma Hits 80-Plus Relative Strength Rating Benchmark
finance.yahoo.com - December 21 at 10:32 AM
Acceleron Pharma Sees Unusually High Options Volume (XLRN)Acceleron Pharma Sees Unusually High Options Volume (XLRN)
www.americanbankingnews.com - December 21 at 1:12 AM
Acceleron Pharma Inc. (XLRN)Acceleron Pharma Inc. (XLRN)
finance.yahoo.com - December 20 at 4:22 PM
Stocks Showing Improved Relative Strength: Acceleron PharmaStocks Showing Improved Relative Strength: Acceleron Pharma
finance.yahoo.com - December 19 at 10:34 AM
Acceleron Pharma Inc. (XLRN) Director Jean George Sells 105,122 SharesAcceleron Pharma Inc. (XLRN) Director Jean George Sells 105,122 Shares
www.americanbankingnews.com - December 18 at 5:24 PM
Acceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : December 14, 2017Acceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : December 14, 2017
finance.yahoo.com - December 14 at 10:42 AM
Acceleron Pharma Sees RS Rating Climb To 74Acceleron Pharma Sees RS Rating Climb To 74
finance.yahoo.com - December 12 at 10:59 AM
Acceleron Pharmas (XLRN) Hold Rating Reiterated at OppenheimerAcceleron Pharma's (XLRN) Hold Rating Reiterated at Oppenheimer
www.americanbankingnews.com - December 12 at 8:48 AM
Acceleron Pharma (XLRN) Receives Buy Rating from HC WainwrightAcceleron Pharma (XLRN) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - December 11 at 4:28 PM
Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of HematologyAcceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology
finance.yahoo.com - December 10 at 10:23 AM
5 Health Care Stocks Gurus Are Buying5 Health Care Stocks Gurus Are Buying
finance.yahoo.com - December 7 at 4:39 PM
Acceleron to Host Conference Call and Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meeting and ExpositionAcceleron to Host Conference Call and Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meeting and Exposition
finance.yahoo.com - December 5 at 12:17 PM
$3.37 Million in Sales Expected for Acceleron Pharma Inc. (XLRN) This Quarter$3.37 Million in Sales Expected for Acceleron Pharma Inc. (XLRN) This Quarter
www.americanbankingnews.com - December 3 at 6:50 AM
Acceleron Pharma Inc. (XLRN) Expected to Post Quarterly Sales of $3.37 MillionAcceleron Pharma Inc. (XLRN) Expected to Post Quarterly Sales of $3.37 Million
www.americanbankingnews.com - December 3 at 6:00 AM
Acceleron Pharma Inc. (XLRN) Receives Average Rating of "Buy" from AnalystsAcceleron Pharma Inc. (XLRN) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 1 at 5:12 PM
Zacks: Brokerages Anticipate Acceleron Pharma Inc. (XLRN) to Post -$0.61 Earnings Per ShareZacks: Brokerages Anticipate Acceleron Pharma Inc. (XLRN) to Post -$0.61 Earnings Per Share
www.americanbankingnews.com - December 1 at 2:14 PM
Acceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : November 20, 2017Acceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : November 20, 2017
finance.yahoo.com - November 20 at 12:24 PM
Acceleron Pharma Inc. (XLRN) Receives "Hold" Rating from Oppenheimer Holdings, Inc.Acceleron Pharma Inc. (XLRN) Receives "Hold" Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 19 at 10:20 PM
Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific SessionsAcceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions
finance.yahoo.com - November 16 at 9:31 AM
Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuireAcceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire
finance.yahoo.com - November 16 at 9:31 AM
Corporate News Blog - Loxo Oncology Collaborates with Bayer to Develop and Commercialize Larotrectinib and LOXO-195Corporate News Blog - Loxo Oncology Collaborates with Bayer to Develop and Commercialize Larotrectinib and LOXO-195
finance.yahoo.com - November 16 at 9:31 AM
Acceleron Pharma Inc. (XLRN) PT Set at $51.00 by Credit Suisse GroupAcceleron Pharma Inc. (XLRN) PT Set at $51.00 by Credit Suisse Group
www.americanbankingnews.com - November 14 at 10:52 AM
FY2017 Earnings Forecast for Acceleron Pharma Inc. (XLRN) Issued By Oppenheimer HoldingsFY2017 Earnings Forecast for Acceleron Pharma Inc. (XLRN) Issued By Oppenheimer Holdings
www.americanbankingnews.com - November 10 at 12:26 PM
FY2017 EPS Estimates for Acceleron Pharma Inc. (XLRN) Decreased by AnalystFY2017 EPS Estimates for Acceleron Pharma Inc. (XLRN) Decreased by Analyst
www.americanbankingnews.com - November 9 at 6:20 AM
Edited Transcript of XLRN earnings conference call or presentation 7-Nov-17 1:00pm GMTEdited Transcript of XLRN earnings conference call or presentation 7-Nov-17 1:00pm GMT
finance.yahoo.com - November 7 at 9:09 PM
Acceleron Pharma Inc. (XLRN) Issues  Earnings Results, Misses Expectations By $0.02 EPSAcceleron Pharma Inc. (XLRN) Issues Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - November 7 at 4:20 PM
Notable Tuesday Option Activity: XLRN, SHLD, ZNotable Tuesday Option Activity: XLRN, SHLD, Z
www.thestreet.com - November 7 at 4:08 PM
The Stumbling Blocks Of Celgene-Dependent Acceleron And Why You Should Hedge Your BetsThe Stumbling Blocks Of Celgene-Dependent Acceleron And Why You Should Hedge Your Bets
seekingalpha.com - November 7 at 4:08 PM
Acceleron Pharma Reports Third Quarter 2017 Operational and Financial ResultsAcceleron Pharma Reports Third Quarter 2017 Operational and Financial Results
finance.yahoo.com - November 7 at 4:08 PM
Acceleron reports 3Q lossAcceleron reports 3Q loss
finance.yahoo.com - November 7 at 4:08 PM
HC Wainwright Boosts Acceleron Pharma Inc. (XLRN) Price Target to $62.00HC Wainwright Boosts Acceleron Pharma Inc. (XLRN) Price Target to $62.00
www.americanbankingnews.com - November 7 at 3:52 PM
Acceleron Pharma, Inc. – Value Analysis (NASDAQ:XLRN) : November 6, 2017Acceleron Pharma, Inc. – Value Analysis (NASDAQ:XLRN) : November 6, 2017
finance.yahoo.com - November 6 at 3:21 PM
Acceleron Pharma Inc. (XLRN) Given Average Recommendation of "Buy" by BrokeragesAcceleron Pharma Inc. (XLRN) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 6 at 1:58 PM
Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : November 3, 2017Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : November 3, 2017
finance.yahoo.com - November 5 at 8:22 AM
Acceleron Pharmas (XLRN) "Hold" Rating Reiterated at Royal Bank Of CanadaAcceleron Pharma's (XLRN) "Hold" Rating Reiterated at Royal Bank Of Canada
www.americanbankingnews.com - November 2 at 2:44 PM

SEC Filings

Acceleron Pharma (NASDAQ:XLRN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Acceleron Pharma (NASDAQ:XLRN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Acceleron Pharma (NASDAQ XLRN) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.